Recent articles
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
Could the world's best-selling drug have a protégé?
Amicus Therapeutics: Is This Biotech an Orphan Underdog?
After months of crazy volatility, the stock seems to have made up its mind on which direction to go: up
Celgene's Next Blockbuster: What You Need to Know
Could Celgene's newest drug finally get this company the respect it deserves?
Omeros: Can the Growth Story Continue?
After a 60% increase since the start of 2017, can shares continue to move higher?
Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?
Does Zogenix stand a chance against the cannabis king?
With Ardelyx's Fall, Does Synergy Now Have a Clear Path to Victory?
Shares of Synergy are down, but things are looking up for this GI gem
Two Red Hot Biotechs With Big Near-term Catalysts Ahead
June will be a pivotal month for shareholders of Portola Pharmaceuticals and Neos Therapeutics
Could This Tiny Biotech Be the David to Mylan's EpiPen Goliath?
Adamis is working on an EpiPen alternative, and the payoff could be huge
Biogen and Alzheimer’s: There’s a Fundamental Problem Here
Biogen's "moonshot" will likely end in failure
Acadia Pharmaceuticals May Just Be the Best Long-Term Play on the Alzheimer's Disease Treatment Market
After a significant pullback in April, is now the right time to jump into Acadia?
Axovant: A New CEO Doesn't Change Anything
A hedge fund founder and a once-failed drug are a recipe for disaster
Why Shares of Portola Pharmaceuticals Are Up Over 60% in 2017
A combination one-two punch has left investors cheering
Amgen's Offering a Money Back Guarantee for Repatha. Will It Be Enough?
After a slow start, are sales of Repatha finally about to pick up?
Sanofi Buying Flexion: A Smart Move?
Will Sanofi acquire anything? Or is this deal smarter than it seems?
Bill Ackman Just Gave Up on Valeant. Should You Too?
What lessons should investors learn from Ackman's greatest mistake?
Aurinia Pharmaceuticals: Where to From Here?
After dropping more than 30% off its highs, is now the time to buy this baby biotech?
Battle in the Boardroom: What's Next for Immunomedics
Will VenBio successfully negotiate a higher bid for IMMU-132?
Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017
Will shares move higher? Or will a boardroom battle leave this biotech cruising for a bruising?
After Years of Stagnation, Are Shares of Rigel Pharmaceuticals About to Take off Into the Stratosphere?
Beneath the surface, Rigel has been gearing up for an explosive 2017
Omeros: Power in the Pipeline
This tiny biotech could be Alexion's worst nightmare